Advances in immunotherapy and new strategies for gastrointestinal stromal tumor

doi:10.3877/cma.j.issn.1674-3946.2023.01.025

Abstract

Abstract:

Gastrointestinal stromal tumors（GIST），soft tissue tumors derived from Cajal stromal cells，are a common type of gastrointestinal sarcoma. The discovery of targeted drugs has greatly improved the survival rate of GIST，and imatinib，as a targeted drug，has become the first-line treatment for GIST. However，recent studies have found that most patients have developed resistance to imatinib. Recent studies have shown that immunotherapy，including combination therapy based on immune checkpoint inhibitors and imatinib，cytokines，anti-kit antibodies，bisspecific monoclonal antibody therapy，and other novel strategies，are also effective in treating gastrointestinal stromal tumors. In this review，the role of immunotherapy and other novel strategies in the treatment of gastrointestinal stromal tumors will be discussed.

Key words: Gastrointestinal Stromal Tumors, Immunotherapy, New Strategy

Chen Lin, Meng Wang, Wenxian Guan, Feng Wang. Advances in immunotherapy and new strategies for gastrointestinal stromal tumor[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(01): 98-100.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2023.01.025

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2023/V17/I01/98

References 34

[1]	中国临床肿瘤学会胃肠间质瘤专家委员会，中国抗癌协会胃肠间质瘤专业委员会，中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 胃肠间质瘤基因检测与临床应用的中国专家共识（2021版）［J］. 临床肿瘤学杂志，2021，26（10）：920-927.
[2]	Zhu CZ，Liu D，Kang WM，et al. Ghrelin and gastrointestinal stromal tumors［J］. World J Gastroenterol，2017，23（10）：1758-1763.
[3]	Serrano C，Marino-Enriquez A，Tao DL，et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours［J］. Br J Cancer，2019，120（6）：612-620.
[4]	王峰，宋鹏，汪灏，等. 284例胃间质瘤临床特征及预后分析［J/CD］. 中华普外科手术学杂志（电子版），2017，11（02）：123-126.
[5]	Boichuk S，Galembikova A，Mikheeva E，et al. Inhibition of FGF2-Mediated Signaling in GIST-Promising Approach for Overcoming Resistance to Imatinib［J］. Cancers（Basel），2020，12（6）：1674.
[6]	Heinrich MC，Jones RL，Mehren MV，et al. Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor（GIST）［J］. J Clin Oncol，35，2017：11011-11011.
[7]	张玉，缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中国专家共识［J］. 中国医院药学杂志，2021，41（20）：2041-2049.
[8]	Lin JX，Chen QF，Zheng CH，et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor？A study based on long-term follow-up［J］. J Cancer Res Clin Oncol，2017，143（4）：727-734.
[9]	于恒，杜尚策，徐恩，等. 影响胃肠道间质瘤预后因素的研究进展［J/CD］. 中华普外科手术学杂志（电子版），2020，14（01）：97-100.
[10]	王峰，于恒，王萌，等. 中高危险度胃肠间质瘤患者术后治疗的预后分析［J/CD］. 中华普外科手术学杂志（电子版），2021，15（04）：460-463.
[11]	张宁，刘蓉，丁乾坤. 舒尼替尼治疗伊马替尼耐药胃肠间质瘤的疗效观察［J］. 中国肿瘤临床与康复，2021，28（05）：590-594.
[12]	魏星. 免疫治疗［J］. 中国科技术语，2019，21（02）：79-80.
[13]	Sun J，Zheng Y，Mamun M，et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors［J］. Biomedi Pharmacother，2020，129：110504.
[14]	Vallilas C，Sarantis P，Kyriazoglou A，et al. Gastrointestinal Stromal Tumors（GISTs）：Novel Therapeutic Strategies with Immunotherapy and Small Molecules［J］. Int J Mol Sci，2021，22（2）：493.
[15]	Pantaleo MA，Tarantino G，Agostinelli C，et al. Immune microenvironment profiling of gastrointestinal stromal tumors（GIST）shows gene expression patterns associated to immune checkpoint inhibitors response［J］. Oncoimmunology，2019，8（9）：e1617588.
[16]	Blakely AM，Matoso A，Patil PA，et al. Role of immune microenvironment in gastrointestinal stromal tumours［J］. Histopathology，2018，72（3）：405-413.
[17]	Labadie BW，Bao R，Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis［J］. Clin Cancer Res，2019，25（5）：1462-1471.
[18]	D'Angelo SP，Shoushtari AN，Keohan ML，et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas：A Phase Ib Study of Dasatinib plus Ipilimumab［J］. Clin Cancer Res，2017，23（12）：2972-2980.
[19]	Dugage MR，Jones RL，Trent J，et al. Beyond the Driver Mutation：Immunotherapies in Gastrointestinal Stromal Tumors［J］. Front Immunol，2021，12：715727.
[20]	Marcq E，Siozopoulou V，De Waele J，et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma［J］. Oncoimmunology，2017，6（1）：e1261241.
[21]	Zhao R，Song Y，Wang Y，et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway［J］. Cell Prolif，2019，52（3）：e12571.
[22]	Zhang JQ，Zeng S，Vitiello GA，et al. Macrophages and CD8（+）T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors［J］. Cancer immunol Res，2018，6（4）：434-447.
[23]	Tan Y，Trent JC，Wilky BA，et al. Current status of immunotherapy for gastrointestinal stromal tumor［J］. Cancer Gene Ther，2017，24（3）：130-133.
[24]	Zhang Y，Zhang Z. The history and advances in cancer immunotherapy：understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications［J］. Cell Mol Immunol，2020，17（8）：807-821.
[25]	Abrams T，Connor A，Fanton C，et al. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors［J］. Clin Cancer Res，2018，24（17）：4297-4308.
[26]	Abrams T，Connor A，Fanton C，et al. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody Drug Conjugate against Mutant and Wild Type c-KIT Positive Solid Tumors［J］. Clinical Cancer Res，2018，24（17）：4297-4308.
[27]	Loaiza-Bonilla A，Bonilla-Reyes PA. Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors：Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy［J］. Cureus，2017，9（9）：e1710.
[28]	Yuki K，Cheng N，Nakano M，et al. Organoid Models of Tumor Immunology［J］. Trends Immunol，2020，41（8）：652-664.
[29]	Bader JE，Voss K，Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy［J］. Mol Cell，2020，78（6）：1019-1033.
[30]	Leko V，Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors［J］. Cancer Cell，2020，38（4）：454-472.
[31]	Andrejeva G，Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors［J］. Cell Metab，2017，26（1）：49-70.
[32]	Garcia-Valverde A，Rosell J，Sayols S，et al. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor［J］. Oncogene，2021，40（48）：6614-6626.
[33]	Catalán M，Olmedo I，Faúndez J，et al. Medicinal Chemistry Targeting Mitochondria：From New Vehicles and Pharmacophore Groups to Old Drugs with Mitochondrial Activity［J］. Int J Mol Sci，2020，21（22）：8464.
[34]	Vitiello GA，Medina BD，Zeng S，et al. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor［J］. Clin Cancer Res，2018，24（4）：972-984.

Please choose a citation manager

Content to export